Silo Pharma Secures U.S. Patent for PTSD Treatment Biomarkers, Advancing Clinical Trials

Silo Pharma (NASDAQ: SILO) has achieved a pivotal milestone with the U.S. Patent and Trademark Office issuing a Notice of Allowance for its licensed patent application concerning biomarkers for evaluating prophylactic treatments for stress-induced affective disorders. This patent, designated as U.S. Patent No. 12,329,726 and set to be issued on June 17, 2025, significantly enhances Silo Pharma's intellectual property portfolio around SPC-15, its lead candidate for an intranasal PTSD treatment licensed from Columbia University. CEO Eric Weisblum highlighted the patent's importance, especially as the company gears up for Phase 1 clinical trials of SPC-15, underscoring the potential impact of this NIH-backed development on the treatment of stress-induced psychiatric disorders.

The advancement of SPC-15 into clinical trials represents a critical juncture for Silo Pharma, a developmental-stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases through innovative therapeutics. The company's pipeline also includes SP-26, a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief, and two preclinical programs: SPC-14, targeting Alzheimer’s disease, and SPU-16, aimed at multiple sclerosis. Silo Pharma's collaborative research and development efforts with universities and independent laboratories underscore its commitment to pioneering treatments in both traditional and psychedelic therapies.

This patent allowance not only bolsters Silo Pharma's position in the biopharmaceutical industry but also signals a broader recognition of the potential for psychedelic and novel drug formulations to address complex psychiatric and neurological conditions. As the company progresses with its clinical trials, the implications for patients suffering from PTSD and related disorders could be profound, offering new hope for effective treatments. For more information on Silo Pharma's developments, visit https://www.SiloPharma.com.